New Zealand restricts number of drugs that can undergo priority assessment
This article was originally published in SRA
Executive Summary
New Zealand's drug regulatory authority Medsafe is aiming to cut down on the number of priority assessments it conducts for medicines that address a significant clinical need because it does not have enough resources to deal with the increased number of requests it has received on this front1,2.